A spinout company from the University of Strathclyde has been launched to accelerate the industrial adoption of advanced chemistry manufacturing and control (CMC) and digital medicines manufacturing technologies.
OpenCMC™ has been designed as an innovation gateway to unlock the commercial potential of the advanced CMC innovation portfolio at the Strathclyde-based CMAC. It aims to build on CMAC’s position as a globally recognised centre of excellence in advanced medicines manufacturing.
Through an asset-centric approach and venture-client collaborations, the company provides new routes for partners to engage with emerging technologies at earlier stages of development, accelerating their transition towards industrial deployment. These include next-generation digital and self-learning manufacturing platforms designed to accelerate development, improve process understanding and support more efficient and sustainable production of medicines.
Innovative model
Massimo Bresciani, CMAC Industry Director and co-founder of the new company, said: “OpenCMC™ introduces an innovative commercial model designed to unlock the transition of CMAC’s technology portfolio into scalable industrial platforms.
“As a global centre of excellence, CMAC has developed a unique portfolio of Data Factories™ and digital capabilities that position it at the forefront of advanced medicines manufacturing. The new company provides a dedicated mechanism to translate these validated assets into investable industrial opportunities, accelerating the digital transformation of chemistry manufacturing and control, enabling coordinated industry adoption and reinforcing CMAC’s long-term sustainability and international leadership.”
Unlock potential
Alastair Florence, co-founder of OpenCMC™ and Director of CMAC, said: “University spinouts play a vital role in translating world-class research into real industrial and societal impact. The new company is an exciting development designed to unlock the potential of CMAC’s growing technology portfolio and accelerate innovation in digital CMC and advanced medicines manufacturing.
“This milestone reflects the strength of our research community and partnerships and the innovative OpenCMC™ model creates new opportunities to move technologies from the laboratory into industrial application.
We are committed to building a sustained pathway to adoption for CMAC’s technologies, helping bring new medicines to patients faster, more efficiently and more sustainably.
OpenCMC™ will lead the commercial validation, execution and delivery of technologies licensed from CMAC, supporting their transition into scalable industrial applications and coordinated industry adoption.
Chemistry, Manufacturing and Controls encompasses the activities required to ensure the safety, efficacy and quality of pharmaceutical products across the entire development lifecycle, from early discovery through to commercial manufacturing and supply.